ARQT 241220 17.50C (ARQT241220C17500) Stock Options, News & Quotes

US OptionsDetailed Quotes

ARQT241220C17500

Watchlist

0.05
0.000.00%

15min DelayClose Nov 22 15:59 ET

0.00High0.00Low

Intraday

5D
Daily

News

Bears Are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now
Zacks Nov 19 09:05 ET
Arcutis' ZORYVE (Roflumilast) Awarded Best Eczema Treatment by Glamour
Arcutis BiotherapeuticsNov 13 08:00 ET
Express News | Arcutis Biotherapeutics Inc : Guggenheim Raises Target Price to $29 From $27
ReutersNov 8 07:28 ET
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $18
Moomoo NewsNov 7 07:31 ET · Ratings
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19
Moomoo NewsNov 7 06:33 ET · Ratings
Arcutis Biotherapeutics Price Target Maintained With a $18.00/Share by Needham
Dow JonesNov 7 06:32 ET · Ratings

Comments

Jaguar8

Nov 13 16:07

13G

$Arcutis Biotherapeutics (ARQT.US)$
Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rubric Capital Management LP(9.38%),David Rosen(9.38%)

MommaCrazy

Oct 22 18:50

$Arcutis Biotherapeutics (ARQT.US)$ Blackrock bought over 9mil shares today.

MommaCrazy

Oct 20 20:26

$Arcutis Biotherapeutics (ARQT.US)$ This should rebound in the morning. 🙏
Long-term! 😜

Trytosaveabit

Oct 18 07:21

News

$Arcutis Biotherapeutics (ARQT.US)$ Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
1 MINUTE AGO, 8:20 AM EDT
VIA GLOBENEWSWIRE

Rocketier (MAXN)

Oct 3 13:14

$Arcutis Biotherapeutics (ARQT.US)$ Shorts will suffer